Compare ALEMBIC LTD with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs GLENMARK PHARMA - Comparison Results

ALEMBIC LTD     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD GLENMARK PHARMA ALEMBIC LTD/
GLENMARK PHARMA
 
P/E (TTM) x 61.4 12.3 500.7% View Chart
P/BV x 2.5 1.6 159.8% View Chart
Dividend Yield % 0.4 0.6 63.4%  

Financials

 ALEMBIC LTD   GLENMARK PHARMA
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
GLENMARK PHARMA
Mar-19
ALEMBIC LTD/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs72712 10.1%   
Low Rs34484 7.0%   
Sales per share (Unadj.) Rs4.7349.6 1.3%  
Earnings per share (Unadj.) Rs6.132.8 18.6%  
Cash flow per share (Unadj.) Rs6.244.3 14.1%  
Dividends per share (Unadj.) Rs0.202.00 10.0%  
Dividend yield (eoy) %0.40.3 112.9%  
Book value per share (Unadj.) Rs40.7198.6 20.5%  
Shares outstanding (eoy) m267.03282.17 94.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.31.7 659.0%   
Avg P/E ratio x8.718.2 47.6%  
P/CF ratio (eoy) x8.513.5 62.9%  
Price / Book Value ratio x1.33.0 43.3%  
Dividend payout %3.36.1 53.7%   
Avg Mkt Cap Rs m14,139168,625 8.4%   
No. of employees `000NA12.0 0.0%   
Total wages/salary Rs m20720,561 1.0%   
Avg. sales/employee Rs ThNM8,196.0-  
Avg. wages/employee Rs ThNM1,708.1-  
Avg. net profit/employee Rs ThNM768.5-  
INCOME DATA
Net Sales Rs m1,25598,655 1.3%  
Other income Rs m3702,081 17.8%   
Total revenues Rs m1,625100,736 1.6%   
Gross profit Rs m11115,858 0.7%  
Depreciation Rs m383,259 1.2%   
Interest Rs m23,346 0.1%   
Profit before tax Rs m44211,335 3.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m243,756 0.6%   
Profit after tax Rs m1,6309,250 17.6%  
Gross profit margin %8.916.1 55.1%  
Effective tax rate %5.433.1 16.4%   
Net profit margin %129.89.4 1,384.9%  
BALANCE SHEET DATA
Current assets Rs m1,86766,968 2.8%   
Current liabilities Rs m59140,211 1.5%   
Net working cap to sales %101.627.1 374.8%  
Current ratio x3.21.7 189.6%  
Inventory Days Days9483 113.1%  
Debtors Days Days7481 90.6%  
Net fixed assets Rs m1,79133,322 5.4%   
Share capital Rs m534282 189.3%   
"Free" reserves Rs m10,32455,770 18.5%   
Net worth Rs m10,85856,052 19.4%   
Long term debt Rs m4135,738 0.1%   
Total assets Rs m11,591132,888 8.7%  
Interest coverage x260.94.4 5,945.9%   
Debt to equity ratio x00.6 0.6%  
Sales to assets ratio x0.10.7 14.6%   
Return on assets %14.19.5 148.5%  
Return on equity %15.016.5 91.0%  
Return on capital %15.217.8 85.3%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1962,998 0.0%   
Fx outflow Rs m26422,859 1.2%   
Net fx Rs m-24440,140 -0.6%   
CASH FLOW
From Operations Rs m23613,242 1.8%  
From Investments Rs m-224-6,990 3.2%  
From Financial Activity Rs m-27-7,387 0.4%  
Net Cashflow Rs m-15-2,971 0.5%  

Share Holding

Indian Promoters % 64.0 48.3 132.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 6.9 2.9%  
FIIs % 9.7 34.4 28.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 10.5 248.6%  
Shareholders   54,701 56,727 96.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   TTK HEALTHCARE  SUVEN LIFESCIENCES  CIPLA  AJANTA PHARMA  VENUS REMEDIES  

Compare ALEMBIC LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 161 Points Lower; Telecom and Metal Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day and ended lower, tracking weakness in global markets owing to coronavirus outbreak.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

Buy this 'Crorepati Stock' and You Could End Up Stinking Rich(Profit Hunter)

Feb 5, 2020

I'm talking about an individual small cap stock that could go up so many times that they make their investors stinking rich in the process. You definitely want to know more...

This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years)(Profit Hunter)

Feb 11, 2020

A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.

Will Your Trade Go Up or Down Today?(Fast Profits Daily)

Feb 5, 2020

How you can find out which way your trade is likely to move on any given trading day.

Will Algo Traders Take Away All Your Profits?(Fast Profits Daily)

Feb 11, 2020

How to fight back against algo trading systems.

No Change in My Long-Term View on the Rebirth of India Stocks(The 5 Minute Wrapup)

Feb 6, 2020

Why the recent post budget volatility has not affected my bullish view on the Rebirth of India stocks.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Feb 18, 2020 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD - BIOCON COMPARISON

COMPARE ALEMBIC LTD WITH

MARKET STATS